Quick ASCO Preview: RASolute 302 Full Data Details Informative on Margin

Research evidence excerpt

Quick ASCO Preview: RASolute 302 Full Data Details Informative on Margin

USA | Biotechnology

REVOLUTION Medicines EquityMayResearch19, 2026

FLASH NOTEQuick ASCO Preview: RASolute 302 Full Data

RATING BUYDetails Informative on Margin

PRICE $144.37^

RVMD will present full Ph3 RASolute 302 data in the plenary session at ASCO

on May 31. We already got very impressive topline OS, but a few key details PRICE TARGET | % TO PT $185.00 | +28%

will help fill in the blanks: DOT impt for revenue outlook, tolerability will be key 52W HIGH-LOW $155.70 - $34.00

to understand dose delivery, and RASmt vs RASwt efficacy may inform testing FLOAT (%) | ADV MM (USD) 85.2% | 542.43

considerations. We cont to see a clear path to further upside for RVMD on fast MARKET CAP $32.2B

darax approval + NSCLC/CRC combo data. TICKER RVMD ^Prior trading day's closing price unless otherwise

noted.

Big picture view - key metrics at ASCO:

Duration of therapy >> given 13.2mo OS, we think median DOT >8mos would be encouraging•

We think this could look even better in real world... albeit there are offsetting effects •

of treat-beyond-progression vs heterogeneous patient pop

Safety, especially rash >> we think tolerability will be impt to understand, given the large pot'l•

market... benchmarks unclear, but we think Gr 3 rash <10% and a non-shocking rate of AE-driven

dose modification (i.e., <50%) should be fine

Rash somewhat in focus for investors •

OS in RASwt pts >> We expect a broad label regardless, given RASmt ~90% of PDAC, but•

separation vs ctrl arm in RASwt minority of pts would be good

This hasn't come up w/ investors, more of a nuance to look for •

More detail on what we'll be looking out for:

Duration of therapy >> Longer duration key to maximize revenue potential, and we think >8mos•